Cardinal is buying its way past distribution
- The core business is still drug distribution, a huge sales base with thin margins.
- The growth plan is specialty care, including MSO platforms for gastroenterology, urology, and oncology practices.
- Solaris Health closed for about $1.9 billion and is now ramping distribution volume inside Pharma.
- GLP-1 drugs lift revenue, but management says they do not meaningfully add segment profit.
- The bear case is execution risk, shown by a $184 million goodwill impairment tied to Navista and ION.
A pivot with proof and scars
Cardinal Health is trying to become more than a drug middleman. The company still makes most of its sales by moving branded, generic, and specialty drugs to pharmacies, hospitals, and care sites. That business is large, needed, and low margin.
The bull case is the shift into specialty and physician services. Cardinal has bought GI Alliance, Advanced Diabetes Supply Group, Urology America, and Solaris Health. Solaris closed on November 3, 2025 for about $1.9 billion, and sits inside The Specialty Alliance, the company’s multi-specialty management services platform.
The bear case is that the pivot is expensive and hard. The OptumRx contract expired in June 2024 after representing 17% of fiscal 2024 revenue, leaving a major volume gap. GLP-1 drugs are also making sales look better than profits. In Q3 fiscal 2026, management said GLP-1 growth was generally offset by a 6 percentage point revenue headwind from IRA WAC pricing adjustments, and GLP-1 sales did not meaningfully add segment profit.
The clearest warning sign is the $184 million pre-tax goodwill impairment for Navista and ION in Q3 fiscal 2026. It does not kill the specialty thesis, but it shows that integration and business model changes are already biting. The stock story now depends on whether Cardinal can turn recent deals into steady profit, not just larger revenue.
Thin spread, higher service bets
Cardinal buys, sources, and distributes healthcare products. In the Pharma segment, it earns a spread for moving drugs through the system. Its Red Oak Sourcing venture with CVS Health helps it buy generic drugs more efficiently.
The company also makes and sources Cardinal Health branded medical, surgical, and lab products. That work lives mainly in Global Medical Products and Distribution. This segment can offer better product control, but it is exposed to tariffs, supplier quality issues, and freight costs.
The newer model is physician practice support. A management services organization, or MSO, helps doctors run the business side of a practice. Cardinal now has gastroenterology, urology, and oncology MSO platforms. If this works, the company gets more profit per dollar of revenue than in basic distribution.
Where it breaks is simple: big customers can leave, drug mix can dilute margins, and acquisitions can disappoint. Cardinal has already shown both sides in fiscal 2026, with higher non-GAAP earnings and a real impairment charge tied to one specialty platform.
What Cardinal sells and runs
Pharmaceutical distribution
This is the main engine. Cardinal distributes branded, generic, specialty, and over-the-counter drugs to retailers, hospitals, and other care sites.
Specialty pharmaceutical services
Specialty drugs support the company’s push into higher value care areas. Growth is helped by branded and specialty pharmaceutical sales from existing and new customers.
Physician MSO platforms
The Specialty Alliance includes GI Alliance, Urology America, Solaris Health, and other practices. Navista and ION cover oncology, but the $184 million impairment shows this is not a risk-free buildout.
Medical products and distribution
Cardinal manufactures and sources branded general, specialty medical, surgical, and lab products. Tariffs and product quality issues can pressure this area.
at-Home Solutions
This business serves patients at home and now includes Advanced Diabetes Supply Group. The ADS deal added a diabetes supplies provider that serves about 500,000 patients annually.
Nuclear, precision health, and logistics
Nuclear and Precision Health Solutions and OptiFreight Logistics sit in Other. In Q3 fiscal 2026, Other grew because of at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
Pharma still dominates the mix
Segment mix uses revenue for the nine months ended March 31, 2026. Pharmaceutical and Specialty Solutions was about 92% of segment revenue, so customer concentration and drug mix matter more than they would in a balanced company.
What could go wrong
OptumRx volume gap
High impact · Medium oddsThe OptumRx contract expired in June 2024 and represented 17% of fiscal 2024 revenue. Cardinal has been trying to replace the lost volume with new customers, growth from existing customers, and cost savings. If replacement volume is lower quality or slower than planned, profit can lag sales.
Specialty deal integration
High impact · Medium oddsCardinal has spent heavily to build specialty and physician services. Solaris alone cost about $1.9 billion in cash, and the company owns about 76% of The Specialty Alliance after that closing. The $184 million Navista and ION goodwill impairment shows that some assumptions have already been cut.
Revenue growth without margin
Medium impact · High oddsGLP-1 drugs are helping reported sales, but management says those sales did not meaningfully contribute to segment profit. In Q3 fiscal 2026, GLP-1 growth was generally offset by a 6 percentage point revenue headwind from IRA WAC pricing adjustments. That makes headline growth less useful as a profit signal.
Opioid settlement cash drain
High impact · High oddsCardinal is part of a National Opioid Settlement Agreement to pay $6.3 billion over 18 years. At March 31, 2026, it had $4.3 billion accrued for certain national opioid settlements, with most remaining payments expected through 2038. During the first nine months of fiscal 2026, opioid litigation payments totaled $417 million.
Tariffs and product quality
Medium impact · Medium oddsCardinal paid about $200 million in IEEPA tariffs by Q3 fiscal 2026. The Supreme Court ruled those tariffs unlawful, but management expects only about half of any recovery to benefit Cardinal because some price increases would be repaid to customers. The company also disclosed an FDA warning letter related to plastic syringes sourced from a third party in China.
Drug pricing and public program rules
Medium impact · Medium oddsNew policy risk sits over branded pharmaceuticals. The Most-Favored Nation drug pricing executive order may affect sales or profit, and the possible adoption of OBBBA could reduce participation in Medicare and Medicaid programs. The impact is uncertain, but this is a real overhang for a company tied to drug volume and healthcare utilization.
In one breath
What does Cardinal Health actually do?
Cardinal Health distributes drugs and medical products to pharmacies, hospitals, clinics, and other care sites. It also owns growing specialty physician services platforms that help practices handle the business side of care.
Why is Cardinal buying physician practices and MSO platforms?
Basic drug distribution is a huge but thin-margin business. MSO platforms in gastroenterology, urology, and oncology could give Cardinal higher-margin service revenue and closer ties to specialty care.
Why can revenue growth be misleading for Cardinal Health?
Some fast-growing products, like GLP-1 drugs, add a lot of sales but little profit. In Q3 fiscal 2026, management said GLP-1 sales did not meaningfully add segment profit, while IRA WAC pricing adjustments offset their revenue lift.
What is the biggest risk to the Cardinal Health thesis?
The biggest risk is that the specialty acquisition plan does not earn enough return. The $184 million impairment for Navista and ION is an early sign that not every deal may perform as first expected.